CoChat

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Open access
Rudin, Charles M., Brahmer, Julie R., Juergens, Rosalyn A., Hann, Christine L., Ettinger, David S., Sebree, Rosa, Smith, Ruth, Aftab, Blake T., Huang, Peng, Liu, Jun O. · 2013 · Journal of Thoracic Oncology
Cited by 145

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Introduction: Preclinical studies have suggested that the oral antifungal agent itraconazole specifically inhibits proliferation, migration, and tube formation of endothelial cells. Itraconazole has potent antiangiogenic activity and enhances the efficacy of cytotoxic chemotherapy in multiple primary xenograft lung cancer models. On the basis of these data, we performed an exploratory clinical study, assessing the efficacy of itraconazole with cytotoxic chemotherapy in the treatment of patients with advanced lung cancer. Methods: The study enrolled patients with progressive nonsquamous non–small-cell lung cancer after one prior cytotoxic therapy for metastatic disease, randomized 2:1 to intravenous administration of pemetrexed 500 mg/m2 on day 1, with or without itraconazole 200 mg orally daily, on a 21-day cycle. Outcome measures included percent progression-free at 3 months, progression-free survival, overall survival, and observed toxicity. Results: A total of 23 patients were enrolled; the study was stopped early because of increasing use of pemetrexed in the first-line setting. At 3 months, 67% of the patients on itraconazole plus pemetrexed were progression-free versus 29% on the control arm of pemetrexed alone (p = 0.11). Median progression-free survivals were 5.5 months (itraconazole) versus 2.8 months (control) (hazard ratio = 0.399, p = 0.089). Overall survival was longer in patients receiving itraconazole (median 32 months) versus control (8 months) (hazard ratio = 0.194, p = 0.012). There were no evident differences in toxicity between the study arms. Conclusion: Itraconazole is well tolerated in combination with pemetrexed. Consistent with our preclinical data, daily itraconazole administration is associated with trends suggestive of improved disease control in patients receiving chemotherapy for advanced lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e31828c3950

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cancer Statistics, 2010

    Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596

  • Cancer statistics, 2012

    Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679

  • Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

    Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×

    “A landmark phase III clinical study, the Eastern Cooperative Oncology Group (ECOG) 4599, randomized 878 patients with advanced nonsquamous NSCLC to a standard chemotherapy doublet with or without bevacizumab.(7) This study demonstrated a statistically significant improvement in both progression-free survival and overa…”
    MethodSelf-citation
  • Inhibition of Angiogenesis by the Antifungal Drug Itraconazole

    Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., & Liu, J. O. (2007) · ACS Chemical Biology · doi:10.1021/cb600362d · Cited by 210 · cited 1×

    “We performed a high throughput screen for agents with previously unsuspected antiangiogenic activity, using differential inhibition of endothelial cell proliferation as an initial assay.(10) Itraconazole was found to be among the most potent and selective inhibitors of endothelial cell proliferation, with IC 50 of 0.”
    MethodSelf-citation
  • Itraconazole Inhibits Angiogenesis and Tumor Growth in Non–Small Cell Lung Cancer

    Aftab, B. T., Dobromilskaya, I., Liu, J. O., & Rudin, C. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0691 · Cited by 167 · cited 3×

    “Use of itraconazole in vivo was associated with tumor hypoxia, as shown by induction of tumor-specific expression of hypoxia inducible factor-1α (HIF-1α), as well as decreased tumor microvessel density, and tumor vascular area.(11) Taken together, these data support the hypothesis that itraconazole may have substantia…”
    BackgroundMethodResultInfluentialSelf-citation

Show all 5 references

Cited by

See all 145

Metadata

Authors
Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R., Aftab, B. T., Huang, P., & Liu, J. O.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2013-05
Volume
8
Issue
5
Pages
619-623
ISSN
1556-0864 (ISSN-L)
OpenAlex
W1991248698
Cited by
145
References
5
FWCI
8.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1097/jto.0b013e31828c3950
The paper
Rudin, C. M., Brahmer, J. R., Juergens, R. A., Hann, C. L., Ettinger, D. S., Sebree, R., Smith, R., Aftab, B. T., Huang, P., & Liu, J. O. (2013). Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0b013e31828c3950

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.